Business Context and Reporting Period
This Form 8-K Current Report was filed by BioRestorative Therapies, Inc. on January 16, 2018. The filing primarily addresses the appointment of a new senior executive and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the compensation package for the new executive:
- Base Salary: $250,000 annually for the initial three months, increasing to $350,000 annually thereafter.
- Performance Bonus: Up to 30% of annual salary based on established performance goals.
- Severance: Three months of salary under certain circumstances.
- Equity Grant: Option to purchase 500,000 shares of common stock at an exercise price of $3.40 per share.
Material Changes
The material change reported is the appointment of Adam D. Bergstein as Senior Vice President, Planning and Business Development, effective January 16, 2018. Mr. Bergstein brings prior experience as the founder of PharmaShield LLC and as a private equity sponsor. No changes to the company's financial position or operational results are reported in this document.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or general outlook commentary. However, it notes a specific condition for the vesting of the new executive's stock options: they will vest and become exercisable upon the initial patient recruitment for the Company's Phase II lumbar clinical trial or a comparable product. The filing includes standard disclaimers regarding the press release furnished under Item 7.01, stating it is not incorporated by reference into registration statements unless specifically identified.
Investor Verification Checklist
- Verify the full terms of the Employment Agreement (Exhibit 10.1) and Stock Option Agreement (Exhibit 10.2) for additional conditions not summarized in the 8-K.
- Confirm the status of the Phase II lumbar clinical trial to assess the timeline for the vesting of the 500,000 share option grant.
- Review the press release (Exhibit 99.1) for any additional strategic context regarding the new hire.
- Check subsequent filings for any impact of this new executive compensation on the company's cash burn rate or dilution.